Thrombin Inhibitor in Venous Thromboembolism III - THRIVE III

Description:

The goal of this trial was to evaluate the efficacy of ximelagatran compared with placebo for the extended secondary prevention of venous thromboembolism after six months of anticoagulant therapy.